Bryostatin 1 induces differentiation and potentiates the antitumor effect of Auristatin PE in a human pancreatic tumor (PANC-1) xenograft model

@article{Mohammad2001Bryostatin1I,
  title={Bryostatin 1 induces differentiation and potentiates the antitumor effect of Auristatin PE in a human pancreatic tumor (PANC-1) xenograft model},
  author={Ramzi M. Mohammad and N. Volkan Adsay and Philip A Philip and George R. Pettit and Vainutis K. Vaitkevicius and Fazlul H. Sarkar},
  journal={Anti-Cancer Drugs},
  year={2001},
  volume={12},
  pages={735-740}
}
Pancreatic cancer has the worst prognosis of all cancers with a dismal 5-year survival rate. Hence, there is a tremendous need for development of new and effective therapy for this tumor. In an earlier study we reported a potent antitumor activity of Auristatin PE (AuriPE) against pancreatic tumor. In addition, we have also reported that bryostatin 1 (bryo1) induces differentiation of leukemia cells, but the effect of bryo1 has not been investigated in pancreatic tumors. This is the first… Expand
NF-κB in pancreatic cancer
TLDR
In vivo and in vitro models that mimic the tumorigenic phenotypes in the appropriate histological and molecular concert would be very useful for confirming the suspected role of the pancreatic cancer signature genetic lesions and better understanding the molecular basis of this disease. Expand
Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway.
TLDR
Data suggest that Lupeol can adopt a multi-prong strategy to target multiple signaling pathways leading to induction of apoptosis and inhibition of growth of pancreatic cancer cells, however, further in-depth in vivo studies are warranted. Expand
Retracted: Cisplatin‐induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC‐3 pancreatic tumor xenografts
TLDR
This study focused on testing whether the inactivation of NF‐κB by genistein could enhance cisplatin‐induced cell growth inhibition and apoptosis in BxPC‐3 cells in vitro and antitumor activity of cisPlatin in vivo. Expand
Inhibition of constitutive NF-κB activity by IκBαM suppresses tumorigenesis
TLDR
It is shown that inhibiting constitutive NF-κB activity by expressing IκBαM suppressed the tumorigenicity of a nonmetastatic human pancreatic cancer cell line, PANC-1, in an orthotopic nude mouse model, suggesting that the inhibition of NF-αB signaling can suppress tumorigenesis of pancreaticcancer cells and that the NF-βB signaling pathway is a potential target for anticancer agents. Expand
Marine pharmacology in 2005-2006: antitumour and cytotoxic compounds.
TLDR
A structured review of the antitumour and cytotoxic properties of 136 marine natural products, many of which are novel compounds that belong to diverse structural classes, including polyketides, terpenes, steroids and peptides. Expand
Marine pharmacology in 2001-2: antitumour and cytotoxic compounds.
TLDR
A structured Review of the antitumour and cytotoxic properties of 97 marine natural products, many of them novel compounds that belong to diverse structural classes, including polyketides, terpenes, steroids, and peptides. Expand
Interactions of antimitotic peptides and depsipeptides with tubulin.
  • E. Hamel
  • Chemistry, Medicine
  • Biopolymers
  • 2002
TLDR
Most of the (depsi)peptides inhibit the binding of Catharanthus alkaloids to tubulin in a noncompetitive manner, GTP hydrolysis by tubulin, and nucleotide turnover at the exchangeable GTP site on beta-tubulin. Expand
Biosynthesis of natural products in marine bacteria : studies in molecular genetics, phylogeny and structural elucidation
TLDR
The study of biosynthesis opens the possibility of solving the supply issue that often prevents the development of drugs from marine natural products and yields novel biochemical reactions and allows insight into the evolution of biosynthetic pathways. Expand
bryA: an unusual modular polyketide synthase gene from the uncultivated bacterial symbiont of the marine bryozoan Bugula neritina.
TLDR
A large modular polyketide synthase (PKS) gene complex from "Candidatus Endobugula sertula" is cloned and one gene, bryA, is characterized, which is proposed to synthesize a portion of the pharmacologically active part of brystatin and may be useful in semisynthesis of clinically useful bryostatin analogs. Expand
Discrete acyltransferases involved in polyketide biosynthesis
TLDR
A summary of information gained from experimental studies on discrete ATs involved in polyketide biosynthesis until the end of 2011 is provided, which represents a novel mechanism of incorporation of branched structures into polyketides. Expand
...
1
2
...

References

SHOWING 1-10 OF 26 REFERENCES
Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.
TLDR
The ability of bryostatin 1 to inhibit the in vitro growth and in vivo development of a panel of four murine tumors of diverse tissue origins and the observation that five of a Panel of six human B-cell lymphoma cell lines were sensitive to the growth inhibitory effects of bRYostatin in vitro suggest that brystatin may be effective in treating lymphoid malignancies in humans. Expand
An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies.
TLDR
The combination of gemcitabine and auristatin-PE is an effective treatment against HPAC tumors in this xenograft model and more effective than treatment with either gem citabine or auristin-PE alone and could be considered for future animal studies with pancreas cancer and/or for human clinical trials. Expand
Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents.
TLDR
The xenograft described herein can be used as an animal model to facilitate the development of novel therapeutic agents against human pancreatic cancers and show that gemcitabine, Ara-C, and Bryostatin 1 were active against KCI-MOH1. Expand
Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents.
TLDR
It is recommended that Bryo1 be considered for clinical investigation in human B-cell tumors and might best be given combined with other chemotherapy agents used in the treatment of that disease. Expand
Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma
TLDR
Auristatin PE is more effective in this model than dolastatin 10, vincristine or bryostatin 1, and auristatinPE can be administered at a concentration 10 times greater than dlastatin10, and there is a synergistic effect between these agents and brystatin 1 which is more apparent in the bryastatin 1 + auristATPE combination. Expand
Discovery of Solid Tumor Active Agents Using a Soft-Agar-Colony-Formation Disk-Diffusion-Assay
TLDR
The history of antitumor drug discovery has essentially been the use of two lymphocytic leukemias of mice as selection funnels through which all agents needed to pass in order to advance toward clinical development, and it is thus not surprising that agents in the clinic are highly active against these tumor systems. Expand
Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines.
TLDR
The results indicate that Bryo1 shows differentiation effects on low-grade FSCCL, intermediate-grade FLCL and high-grade DLCL, and stimulatory or no effect on high- grade SCNCL and has a potential therapeutic role as a B-cell differentiating agent. Expand
Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma.
TLDR
This is the first study illustrating that clonal characteristics of primary pancreatic tumors remained unchanged when implanted in mice and as a permanent cell line grown in vitro; and there is a synergistic effect between gemcitabine and selected marine products tested in this study, which is more apparent in the gemcitABine and auristatin-PE combination. Expand
Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
TLDR
It is concluded that the sequential treatment with Bryo 1 followed by 2-CdA resulted in higher antitumor activity and improved animal survival, and supports the change of CLL to HC. Expand
Bryostatin 1‐Induced Modulation of the Acute Lymphoblastic Leukemia Cell Line Reh
TLDR
The findings indicate that bryo is capable of inducing further differentiation of the Reh cells along the B cell lineage similar to those of TPA. Expand
...
1
2
3
...